CompletedNot applicableNCT00852358

A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I

Studying NON RARE IN EUROPE: Alzheimer disease

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Patricia I. Dickson, M.D.
Principal Investigator: Agnes Chen, MD
Los Angeles Biomedical Institute at Harbor-UCLA
Intervention: laronidase(drug)
Enrollment: 9 enrolled
Eligibility: 6 years · All sexes
Timeline: 2009 – 2015

Study locations (3)

Children's Hospital & Research Center Oakland, Oakland, California, United States
Los Angeles Biomedical Institute at Harbor-UCLA, Torrance, California, United States
University of Minnesota, Minneapolis, Minnesota, United States

Collaborators

The Ryan Foundation · BioMarin Pharmaceutical · Rare Diseases Clinical Research Network · National Center for Advancing Translational Sciences (NCATS) · National Institute of Neurological Disorders and Stroke (NINDS) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · University of Minnesota · University of California, Los Angeles

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00852358 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Alzheimer disease →

← Back to all trials